Showing results (181-190 of 240) with videos related to

Sort By:
Pageof 24
The American Journal of Psychiatry|January 4, 2008
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization StudyMichael F Green, Keith H Nuechterlein, Robert S Kern, et al.
JAMA Psychiatry|October 16, 2024
Antipsychotic Drugs and Cognitive Function: A Systematic Review and Network Meta-AnalysisLena Feber, Natalie L Peter, Virginia Chiocchia, et al.
The American Journal of Psychiatry|March 3, 2007
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE studyT Scott Stroup, Jeffrey A Lieberman, Joseph P McEvoy, et al.
Schizophrenia Research|June 15, 2010
The Cognitive Assessment Interview (CAI): development and validation of an empirically derived, brief interview-based measure of cognitionJoseph Ventura, Steven P Reise, Richard S E Keefe, et al.
The American Journal of Psychiatry|April 6, 2006
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychoticT Scott Stroup, Jeffrey A Lieberman, Joseph P McEvoy, et al.
Schizophrenia Research|May 27, 2017
Deviation from expected cognitive ability across psychotic disordersW C Hochberger, T Combs, J L Reilly, et al.
Schizophrenia Research|September 28, 2014
Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficitLauren E Ethridge, Melanie Soilleux, Paul A Nakonezny, et al.
Biological Psychiatry|September 6, 2005
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosisRichard S E Keefe, Larry J Seidman, Bruce K Christensen, et al.
Schizophrenia Research|September 21, 2005
Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trialDel D Miller, Joseph P McEvoy, Sonia M Davis, et al.
Schizophrenia Bulletin|June 14, 2015
Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of SchizophreniaDavid Walling, Stephen R Marder, John Kane, et al.
Pageof 24